65,437 trials
Hepatitis C
Primary: Percentage of Participants With 12 Week Sustained Virologic Response (SVR12) — 81.7; 42.9 Percentage of participants — p=<0.0001
Cataract
Primary: Use of Corrective Visual Aids (i.e., Spectacles, Contact Lenses) Post Intraocular Lens (IOL) Surgery — 71; 8; 9 participants
Coronary Artery Disease
Primary: Clinical Procedural Success — 100 percentage of participants
Breast Cancer
Primary: Change in Bone Mineral Density (BMD) Measured by Dual (Energy) X-ray Absorptiometry (DXA) at Lumbar Spine (L2-L4) From Baseline to Month 24 — -0.075; 0.037 Z-score
Hepatitis C
Primary: Virological Response at Week 28 (W28VR) — 61; 60 participants — p=0.855
Neck Pain
Primary: Change in Pain Scores on the Visual Analog Scale (VAS: 0-10) After 30 Days — 1.77; 3.34; 8.83 units on a scale
Arthropathy of Knee Joint
Primary: Weight-bearing Ratio During Five Times Sit-to-Stand Test (FTSST) — 0.77; 0.8 ratio — p==0.329
Invasive Aspergillosis
Primary: Number of Subjects With Adverse Events — 1; 1; 1; 1 participants
Severe Hypertension
Primary: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events and Deaths — 20.0; 12.5; 33.3; 48.6 Percentage of participants
Pre-Eclampsia
Primary: Renal Function in Severe Preeclampsia With Restrictive Fluid Therapy — 0.69; 0.73; 0.99; 0.93 mg/dl — p=<0.05
Parkinson's Disease · Motor Symptoms · Akinesia
Primary: Change From Baseline in Average Daily "Time to on" ("TTO") by Subject Diary. — 60.86; 23.72; 37.14 minutes
Leukemia
Primary: Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction Therapy — 91 percentage of analyzable subjects
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving Remission at Week 16 According to DAS28 — 42.8 percentage of participants — p=0.1648
Hepatitis C, Chronic
Primary: Sustained Virological Response (SVR12) — 70.7; 78.6; 76.7; 72.4 percentage of participants — p=<0.0001
Low Risk (0-10% Chance) of Developing Cardiovascular Disease Within 10 Years Based on Risk Factors · Moderate Risk (10-20% Chance) of Developing Cardiovascular (Heart) Disease Within 10 Years Based on Risk Factors
Primary: LDL-C in All ICAT Group Participants Versus Non-ICAT Group Participants — 126.2; 126.0; 103.2; 107.7 mg/dL